2021 Biotech Outlook: Looking Back to Look Ahead

2020 was a rollercoaster year for the biopharma industry. It was also the year the entire industry changed; from a global response to a worldwide pandemic and an unprecedented effort around vaccine development, consideration of a new drug development model, and the emergence of new opportunities that will continue to propel the industry forward. Podcast host Bob Coughlin and his guests, Jeremy Levin, Chairman and Chief Executive Officer at Ovid Therapeutics; and Nina Kjellson, General Partner at Canaan Partners, discuss the impact of the past year and the challenges and opportunities for 2021. To learn more, go to MassBio.org.